Our data highlight LIX1 role in digestive mesenchyme‐derived cell‐fate decisions and identify this novel regulator as a target for drug design for GIST treatment by influencing its differentiation status. This evidence concerns the gene LIX1 and gastrointestinal stromal tumor.